Moderna Begins Human Trials of HIV Vaccine Using mRNA MiguelAngelLuna.mx
go to original January 28, 2022

The company Moderna and the International AIDS Vaccine Initiative (IAVI) reported that they have begun human trials of an HIV vaccine that uses messenger RNA technology, also known as mRNA.

The Phase 1 trial involves 56 HIV-negative adults living in the United States. The goal of the vaccine is to stimulate the production of a type of broadly neutralizing antibodies, or bnAbs, that can act against the many variants of HIV currently circulating.

The vaccine teaches B lymphocytes, which are part of the immune system, to make these antibodies. The volunteers were injected with an immunogen, a substance that can trigger an immune response, and then with a booster immunogen.

Last year the first immunogen was approved but without using messenger RNA technology, it was shown that the desired immune response was triggered in dozens of people who participated in the research. The next step was to incorporate Moderna with its new mRNA technique.

Mark Feinberg, President and CEO of IAVI, was excited about advances in HIV vaccine design using Moderna's mRNA.

See the original at MiguelAngelLuna.mx

This article was translated from Spanish using AI technologies. Errors may exist due to this process.